Home /Biblio

Biblio

Found 399 results
Author Keyword Title Type [ Year(Asc)]
2011
G. C. E. Stuart, Kitchener, H. C., Bacon, M., du Bois, A., Friedlander, M. Leonard, Ledermann, J. A., Marth, C., Thigpen, T., and Trimble, E. L., “2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 750-5, 2011.
S. Pignata, Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., Lombardi, A. V., Febbraro, A., Scollo, P., Ferro, A., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M. R., Aitini, E., Natale, D., Scaltriti, L., Greggi, S., Pisano, C., Lorusso, D., Salutari, V., Legge, F., Di Maio, M., Morabito, A., Gallo, C., and Perrone, F., “Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial”, J Clin Oncol, vol. 29, pp. 3628-35, 2011.
M. S. Anglesio, Carey, M. S., Köbel, M., Mackay, H., and Huntsman, D. G., “Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.”, Gynecol Oncol, vol. 121, no. 2, pp. 407-15, 2011.
G. Freyer and Tinker, A. V., “Clinical trials and treatment of the elderly diagnosed with ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 776-81, 2011.
M. Leonard Friedlander, Trimble, E. L., Tinker, A., Alberts, D. S., Åvall-Lundqvist, E., Brady, M. F., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., Vergote, I. B., Beale, P., Bekkers, R., Calvert, P., Copeland, L., Glasspool, R. M., Gonzalez-Martin, A., Katsaros, D., Kim, J. Won, Miller, B., Provencher, D. M., Rubinstein, L., Atri, M., Zeimet, A. G., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., “Clinical trials in recurrent ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 771-5, 2011.
K. Lim, Small, W., Portelance, L., Creutzberg, C., Jürgenliemk-Schulz, I. M., Mundt, A. J., Mell, L. K., Mayr, N., Viswanathan, A., Jhingran, A., Erickson, B., Santos, J. De Los, Gaffney, D. K., Yashar, C., Beriwal, S., Wolfson, A., Taylor, A., Bosch, W., Naqa, I. El, and Fyles, A., “Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.”, Int J Radiat Oncol Biol Phys, vol. 79, no. 2, pp. 348-55, 2011.
T. J. Herzog, Vermorken, J. B., Pujade-Lauraine, E., Provencher, D. M., Jagiello-Gruszfeld, A., Kong, B., Boman, K., Park, Y. Choi, Parekh, T., Lebedinsky, C., Gómez, J., and Monk, B. J., “Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.”, Gynecol Oncol, vol. 122, no. 2, pp. 350-5, 2011.
F. Joly, Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I. B., Ferrandina, G., Dell'Anna, T., Huober, J., and Pujade-Lauraine, E., “Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.”, Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.
G. J. S. Rustin, Vergote, I. B., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A., Sagae, S., Greven, K., Parmar, M. K. B., Friedlander, M. Leonard, Cervantes, A., Vermorken, J. B., and Intergroup, G. Cancer, “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)”, Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.
L. C, Simes, R. J., Gebski, V., Wollschlaeger, K., Plante, M., Vergote, I. B., Maenpaa, J. U., Ferrero, A., Pisano, C., Parma, G., Berton-Rigaud, D., der W, S., Bentley, J., Reinthaller, A., Schmalfeldt, B., Hirte, H., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, “Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. ”, Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., “Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.”, Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
K. Kudoh, Takano, M., Kouta, H., Kikuchi, R., Kita, T., Miyamoto, M., Watanabe, A., Kato, M., Goto, T., and Kikuchi, Y., “Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers”, Gynecol Oncol, vol. 122, pp. 233-7, 2011.
T. Thigpen, du Bois, A., McAlpine, J., DiSaia, P., Fujiwara, K., Hoskins, W. J., Kristensen, G. B., Mannel, R., Markman, M., Pfisterer, J., Quinn, M., Reed, N. Simon, Swart, A. Marie, Berek, J. S., Colombo, N., Freyer, G., Gallardo, D., Plante, M., Poveda, A. M., Rubinstein, L., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., “First-line therapy in ovarian cancer trials.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 756-62, 2011.
M. Bacon, Kitchener, H. C., Stuart, G. C. E., and Vermorken, J. B., “The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 746-9, 2011.
C. Kurzeder, L, Z., Eisenhauer, E., Vergote, I. B., du Bois, A., D, T., Y, W., JF, G., HW, H., B, R., LC, H., Bentley, J., Wagner, U., Plante, M., Kimmig, R., and Pfisterer, J., “The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. ”, J Clin Oncol , vol. 29, no. suppl; abstr 5088, 2011.
F. A. Raja, Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K. B., Swart, A. Marie, and Ledermann, J. A., “Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.”, Br J Cancer, vol. 105, no. 7, pp. 884-9, 2011.
J. - E. Kurtz, Kaminsky, M. C., Floquet, A., Veillard, A. S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N. Simon, Scambia, G., Varsellona, N., Brown, C., and Pujade-Lauraine, E., “Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.”, Ann Oncol, vol. 22, no. 11, p. 2423, 2011.
M. S. Carey and Gotay, C., “Patient-reported outcomes: clinical trials in ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 782-7, 2011.
T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., and Oza, A. M., “A phase 3 trial of bevacizumab in ovarian cancer.”, N Engl J Med, vol. 365, no. 26, p. 2496, 2011.
, “a phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosied, pre”, N Engl J Med, vol. 365, p. 2483, 2011.
C. Khoon Lee, Simes, R. J., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I. B., Pisano, C., Parma, G., Burges, A., Bourgeois, H., Högberg, T., Bentley, J., Angleitner-Boubenizek, L., Ferrero, A., Richter, B., Hirte, H., Gebski, V., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, “Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.”, Br J Cancer, vol. 105, no. 8, pp. 1144-50, 2011.
P. Harter, Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K. Ulrich, Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., and du Bois, A., “Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.”, Int J Gynecol Cancer, vol. 21, no. 2, p. 295, 2011.
T. Toita, Kato, S., Ishikura, S., Tsujino, K., Kodaira, T., Uno, T., Hatano, K., Sakurai, H., Niibe, Y., Kazumoto, T., Nishimura, T., Kitagawa, R., Fukutani, M., Oguchi, M., Umayahara, K., Hirashima, Y., Aoki, Y., Takizawa, K., and Group, D. Committee, “Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer”, Int J Clin Oncol, vol. 16, pp. 379-86, 2011.
H. Nomura, Aoki, D., Takahashi, F., Katsumata, N., Watanabe, Y., Konishi, I., Jobo, T., Hatae, M., Hiura, M., and Yaegashi, N., “Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).”, Ann Oncol, vol. 22, no. 3, pp. 636-42, 2011.
G. B. Kristensen, Perren, T. J., Qian, W., Pfisterer, J., Ledermann, J. A., Joly, F., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., “Result of interim analysis of overall survival in the phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. ”, J Clin Oncol , vol. 29, no. suppl; abstr LBA5006, 2011.

Pages